p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

被引:121
作者
Fulci, G
Labuhn, M
Maier, D
Lachat, Y
Hausmann, O
Hegi, ME
Janzer, RC
Merlo, A
Van Meir, EG [1 ]
机构
[1] CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland
[2] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA
[4] Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland
[5] CHU Vaudois, Univ Hosp, Dept Neuropathol, CH-1011 Lausanne, Switzerland
关键词
p14arf; p16; mdm2; egfr; brain tumor; tumor suppressor;
D O I
10.1038/sj.onc.1203700
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently: deleted in human tumors, Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci, To examine this question we performed a multigenic analysis on 29 gliomas, We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26, Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis, The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV, either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%), These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and Loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.
引用
收藏
页码:3816 / 3822
页数:7
相关论文
共 49 条
  • [1] Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
    Biernat, W
    Tohma, Y
    Yonekawa, Y
    Kleihues, P
    Ohgaki, H
    [J]. ACTA NEUROPATHOLOGICA, 1997, 94 (04) : 303 - 309
  • [2] BIERNAT W, 1997, NEUROPATHOL EXP NEUR, V56, P180
  • [3] FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS
    CAIRNS, P
    POLASCIK, TJ
    EBY, Y
    TOKINO, K
    CALIFANO, J
    MERLO, A
    MAO, L
    HERATH, J
    JENKINS, R
    WESTRA, W
    RUTTER, JL
    BUCKLER, A
    GABRIELSON, E
    TOCKMAN, M
    CHO, KR
    HEDRICK, L
    BOVA, GS
    ISAACS, W
    KOCH, W
    SCHWAB, D
    SIDRANSKY, D
    [J]. NATURE GENETICS, 1995, 11 (02) : 210 - 212
  • [4] PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
    Chiariello, E
    Roz, L
    Albarosa, R
    Magnani, I
    Finocchiaro, G
    [J]. ONCOGENE, 1998, 16 (04) : 541 - 545
  • [5] Costello JF, 1997, CANCER RES, V57, P1250
  • [6] E1A signaling to p53 involves the p19ARF tumor suppressor
    de Stanchina, E
    McCurrach, ME
    Zindy, F
    Shieh, SY
    Ferbeyre, G
    Samuelson, AV
    Prives, C
    Roussel, MF
    Sherr, CJ
    Lowe, SW
    [J]. GENES & DEVELOPMENT, 1998, 12 (15) : 2434 - 2442
  • [7] PTEN mutations in gliomas and glioneuronal tumors
    Duerr, EM
    Rollbrocker, B
    Hayashi, Y
    Peters, N
    Meyer-Puttlitz, B
    Louis, DN
    Schramm, J
    Wiestler, OD
    Parsons, R
    Eng, C
    von Deimling, A
    [J]. ONCOGENE, 1998, 16 (17) : 2259 - 2264
  • [8] DURO D, 1995, ONCOGENE, V11, P21
  • [9] FRYE RA, 1989, ONCOGENE, V4, P1153
  • [10] The functional role of tumor suppressor genes in gliomas - Clues for future therapeutic strategies
    Fueyo, J
    Gomez-Manzano, C
    Yung, A
    Kyritsis, AP
    [J]. NEUROLOGY, 1998, 51 (05) : 1250 - 1255